相关实验视频

Updated: Sep 15, 2025

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

显著提升 NKT 细胞激动剂的 Th2 选择性活性,由硫胺键设计启用

Yu Wen¹, En-Yang Wang¹, Ye-Hui Wu¹

¹International Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.

Journal of medicinal chemistry

|July 18, 2025

概括

研究人员通过修改αGalCer.开发了一种强大的Th2-biased自然杀手T (NKT) 细胞激动剂,GCS-12-6,通过修改αGalCer. 这种新化合物增强了免疫调节,并显示出治疗炎症状况的前景.

科学领域:

免疫学免疫学免疫学
药物发现药物发现药物发现
结构生物学结构生物学

背景情况:

自然杀手T (NKT) 细胞激动剂对免疫治疗有价值,调节Th1 (促炎) 和Th2 (抗炎) 反应.
与原始化合物αGalCer.相比,现有的Th2偏差NKT激活剂通常具有较低的活性.

研究的目的:

设计和识别使用结构引导的硫胺基改性使用高强度Th2偏差的αGalCer类似物.
增强糖脂/CD1d复合体内的结,以提高激素活性和选择性.

主要方法:

以结构为指导的设计和合成具有硫胺修饰的新型αGalCer类似物.
在体内对同类物质的刺激活性和Th2选择性的评估.
在肠道炎症模型中评估CD1d连接体呈现和治疗疗效.

主要成果:

与αGalCer.相比,化合物GCS-12-6的刺激活性增加了6.7倍,Th2选择性增强了76倍.
GCS-12-6通过抗原呈现细胞展示了快速的CD1d配体呈现.
GCS-12-6提供了有效的保护对实验性肠道炎症.

结论:

GCS-12-6代表了迄今为止开发的最强大的Th2偏差NKT细胞激动剂之一.
基于结构的硫胺基修饰是一种可行的策略,用于创建强效和有偏见的NKT细胞激动剂.
作为炎症性疾病的免疫治疗剂,GCS-12-6具有前景.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...